Treatment with sacubitril/valsartan reduces Insulin-Like Growth Factor Binding Protein-7 concentrations in management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Study

Trial Profile

Treatment with sacubitril/valsartan reduces Insulin-Like Growth Factor Binding Protein-7 concentrations in management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Study

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan (Primary)
  • Indications Heart failure
  • Focus Biomarker; Pharmacodynamics
  • Acronyms PARAMOUNT
  • Most Recent Events

    • 28 Nov 2017 New trial record
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top